J3243 Tigecycline Injection — HCPCS Reimbursement

HCPCS Level II code J3243 denotes a 1 mg injection of tigecycline, an intravenous broad-spectrum antibiotic used in serious bacterial infections. Nationally, accurate coding for parenteral antimicrobials matters for clinical documentation, hospital pharmacy billing, and payer coverage determinations given tigecycline's role in treating complicated infections.

This analysis covers coverage and benchmarking considerations for major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage behavior, common billing practices, and clinical context relevant to tigecycline administration.

The publication outlines what to expect in service-line reporting for inpatient and outpatient settings, presents common modifiers and coding considerations (where provided), and summarizes how payers typically classify parenteral antibiotic services. Clinical context discusses typical uses for tigecycline and implications for billing given its dosing form. Where specific payer policy details or additional coding crosswalks are not provided in the input, the report notes that those items are not available and focuses on universally relevant coding facts and national payer coverage patterns.

Billing Code Overview

HCPCS Level II code J3243 represents an injection of tigecycline, 1 mg. This code is used to bill for the provision of the antibiotic tigecycline administered by injection.

Service type: Intravenous or parenteral antibiotic administration
Typical site of service: Hospital inpatient, hospital outpatient, or other acute care settings where parenteral antimicrobial therapy is delivered

Data not available in the input.

Clinical Context

A typical patient is a hospitalized adult with a complicated intra-abdominal infection, severe skin and soft tissue infection, or multidrug-resistant Gram‑negative infection where standard agents are ineffective or contraindicated. The clinical workflow begins with an infectious disease consult and microbiology results demonstrating an organism susceptible to tigecycline or when empiric broad-spectrum coverage is needed for polymicrobial infections. The pharmacy verifies dosing, prepares the intravenous infusion, and documents lot and dose. Nursing administers the drug intravenously over the recommended infusion time, monitors vital signs and infusion site, and documents administration and any adverse reactions. Orders include the medication J3243 billed per milligram, the indication (ICD‑10 diagnosis linked in the chart), and any applicable modifiers to reflect billing circumstances such as service location or provider status.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier	Use when no billing modifier applies to the service.
`11`	Professional component

Taxonomy Code	Specialty	Notes
`208000000X`	Infectious Disease	ID physicians commonly order and direct tigecycline therapy.
`207RI0200X`	Internal Medicine	Hospitalists frequently manage inpatient antimicrobial therapy orders and coordination.
`363L00000X`	Pharmacy	Clinical pharmacists are responsible for dosing verification, preparation, and drug utilization review.
`164W00000X`	Emergency Medicine	Emergency providers may initiate empiric administration in severe sepsis prior to admission.
`282N00000X`	Registered Nurse	Nursing staff administers IV infusions and monitors the patient.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`A41.9`	Sepsis, unspecified organism	Tigecycline may be used as part of broad-spectrum coverage in severe sepsis when resistant organisms are suspected.
`K65.9`	Peritonitis, unspecified	Complicated intra-abdominal infections often require broad-spectrum IV antibiotics such as tigecycline.
`A49.9`	Bacterial infection, unspecified site	Used when a resistant or polymicrobial infection is suspected and site-specific therapy is pending.
`L03.90`	Cellulitis, unspecified	Severe skin and soft tissue infections, including those due to resistant organisms, may be treated with tigecycline.
`J18.9`	Pneumonia, unspecified organism	In selected cases of multidrug-resistant pneumonia pathogens, tigecycline may be considered.
`B96.2`	Klebsiella pneumoniae as the cause of diseases classified elsewhere	Tigecycline covers certain resistant Gram-negative organisms and may be used when cultures identify such pathogens.
`B96.81`	Enterobacter species as the cause of diseases classified elsewhere	Relevant when Enterobacter is implicated and resistance limits first‑line options.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, therapeutic, prophylactic, or diagnostic; initial, up to 1 hour	Commonly billed for the initial IV infusion administration of an antimicrobial if facility bills infusion services separately.
`96366`	Intravenous infusion, each additional hour	Used when the antimicrobial infusion extends beyond the initial hour and additional time units are billed.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intramuscular or subcutaneous	May be used for single‑dose injections if alternate route used; less common for tigecycline which is IV.
`36415`	Collection of venous blood by venipuncture	Frequently performed for baseline and follow‑up labs (renal, hepatic, therapeutic monitoring) during antibiotic therapy.
`87505`	Infectious agent detection by nucleic acid (e.g., PCR), multiple organisms, direct probe technique	Microbiology or molecular tests that identify pathogens guiding use of tigecycline in resistant infections.

OpenPayer

Summary & Overview

HCPCS J3243: Injection of Tigecycline, 1 mg